TUKYSA Drug Patent Profile

Which patents cover Tukysa, and what generic alternatives are available?

Tukysa is a drug marketed by Seagen and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in forty-four countries.

The generic ingredient in TUKYSA is tucatinib. One supplier is listed for this compound. Additional details are available on the tucatinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Tukysa

Tukysa was eligible for patent challenges on April 17, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 12, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TUKYSA

International Patents:	187
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	17
Patent Applications:	1,312
Drug Prices:	Drug price information for TUKYSA
What excipients (inactive ingredients) are in TUKYSA?	TUKYSA excipients list
DailyMed Link:	TUKYSA at DailyMed

See drug prices for TUKYSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TUKYSA

NDA:

213411

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TUKYSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RemeGen Co., Ltd.	Phase 1/Phase 2
National Cancer Institute (NCI)	Phase 1
Jonathan Riess	Phase 1

See all TUKYSA clinical trials

Pharmacology for TUKYSA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for TUKYSA

TUKYSA is protected by seven US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y	Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No			Y
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-002	Apr 17, 2020		RX	Yes	Yes
Seagen	TUKYSA	tucatinib	TABLET;ORAL	213411-001	Apr 17, 2020		RX	Yes	No

EU/EMA Drug Approvals for TUKYSA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Seagen B.V.	Tukysa	tucatinib	EMEA/H/C/005263Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens.	Authorised	no	no	no	2021-02-11

International Patents for TUKYSA

When does loss-of-exclusivity occur for TUKYSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUKYSA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2377539	Analogues de quinazoline en tant qu'inhibiteurs de kinase de tyrosine de récepteur (Quinazoline analogs as receptor tyrosine kinase inhibitors)
Lithuania	PA2021516
World Intellectual Property Organization (WIPO)	2013142875
Cyprus	1113992
Norway	20061171
Hong Kong	1129678
South Korea	102317166

Supplementary Protection Certificates for TUKYSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1971601	2021C/531	Belgium		PRODUCT NAME: TUCATINIB, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; AUTHORISATION NUMBER AND DATE: EU/1/20/1526 20210212
1971601	SPC/GB21/042	United Kingdom		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU/1/20/1526(FOR NI) 20210212; UK FURTHER MAS ON IPSUM 20210212
1971601	C 2021 022	Romania		PRODUCT NAME: TUCATINIB OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC SAU SOLVAT; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF NATIONAL AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211
1971601	770	Finland
1971601	21C1031	France		PRODUCT NAME: TUCATINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/20/1526 20210212
1971601	LUC00217	Luxembourg		PRODUCT NAME: TUCATINIB EVENTUELLEMENT SOUS FORME D'UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/20/1526 20210212
1971601	2190026-1	Sweden		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NAT. REG. NO/DATE: EU/20/1526 20210212; FIRST REG.: CH 67798 20200507

TUKYSA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Tukysa (tucatinib) is an oral tyrosine kinase inhibitor approved for HER2-positive metastatic breast cancer. Its market trajectory is shaped by competitive landscapes, clinical development, and patent exclusivity.

What is TUKYSA's Approved Indication and Mechanism of Action?

Tukysa is approved by the U.S. Food and Drug Administration (FDA) for patients with advanced unresectable or metastatic HER2-positive breast cancer who have received prior anti-HER2-based treatment in the metastatic setting or who have developed disease progression on or after primary systemic treatment. It is administered in combination with trastuzumab and capecitabine.

The mechanism of action for Tukysa involves the selective inhibition of HER2 (ErbB2) and HER3 (ErbB3) tyrosine kinases. HER2 is a receptor tyrosine kinase that plays a critical role in cell growth and survival. Amplification or overexpression of HER2 is a hallmark of certain breast cancers. By inhibiting HER2, Tukysa blocks downstream signaling pathways that promote tumor cell proliferation and survival. Inhibition of HER3, which dimerizes with HER2, further contributes to blocking oncogenic signaling. [1]

What is the Current Market Landscape for TUKYSA?

The HER2-positive metastatic breast cancer market is characterized by established therapies and emerging entrants. TUKYSA competes with other HER2-targeted agents, including trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (Kadcyla). The emergence of antibody-drug conjugates (ADCs) and newer oral targeted therapies has intensified competition.

Key competitors and their market positions include:

• Kadcyla (ado-trastuzumab emtansine): An ADC that combines trastuzumab with a cytotoxic agent, approved for HER2-positive metastatic breast cancer after prior treatment with trastuzumab and a taxane.
• Enhertu (trastuzumab deruxtecan): Another ADC that has shown significant efficacy across HER2-expressing tumors, including those with low HER2 expression, and has gained market share rapidly.
• Tykerb (lapatinib): An oral tyrosine kinase inhibitor that targets HER2 and EGFR, used in combination with capecitabine for HER2-positive metastatic breast cancer.

The clinical trial data supporting Tukysa's approval, particularly the HER2CLIMB study, demonstrated a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive metastatic breast cancer. [1] However, the clinical profile and efficacy of Tukysa relative to newer agents like Enhertu are continuously evaluated by oncologists and payers.

What are the Key Intellectual Property and Patent Expirations for TUKYSA?

Seagen Inc. (now part of Pfizer) holds the primary intellectual property rights for Tukysa. The patent landscape for pharmaceutical products is critical for determining market exclusivity and forecasting future revenue streams.

Key patent information for Tukysa includes:

• U.S. Patent No. 9,573,831: This patent, titled "PYRIMIDINE AND PYRAZINE DERIVATIVES AS HER2 KINASE INHIBITORS," covers the compound tucatinib. This patent is a foundational patent for the drug.
• Exclusivity Periods: In addition to patent protection, regulatory exclusivities can extend market protection. For instance, New Chemical Entity (NCE) exclusivity in the U.S. provides 5 years of marketing exclusivity.
• Orange Book Listings: The FDA's "Orange Book" lists patents that cover approved drug products. Patents listed for Tukysa indicate the specific intellectual property protecting the drug and its uses. A review of the Orange Book reveals multiple patents associated with tucatinib, covering composition of matter, methods of use, and formulations.

Projected patent expiration dates are crucial for estimating the period of market exclusivity. While specific expiration dates can vary based on patent term extensions and any potential litigation, a general analysis suggests that primary composition of matter patents for Tukysa are expected to expire in the mid-to-late 2030s. For example, U.S. Patent No. 9,573,831 is listed with an expiration date of March 28, 2034. [2]

However, companies often file for secondary patents covering new formulations, manufacturing processes, or methods of use, which can extend exclusivity beyond the primary patent expiration.

What are TUKYSA's Financial Performance and Sales Projections?

Seagen reported significant sales for Tukysa following its launch. Financial performance is driven by market penetration, physician adoption, payer coverage, and the competitive environment.

Tukysa's financial performance metrics:

• 2023 Revenue: Seagen reported net sales of approximately \$803 million for Tukysa in 2023. [3] This represents a substantial increase from previous years, indicating growing market acceptance and utilization.
• Year-over-Year Growth: Tukysa demonstrated strong year-over-year growth in 2023, exceeding 2022 revenues by a significant margin.
• Analyst Projections: Consensus analyst projections for Tukysa's peak sales vary, but many anticipate it reaching or exceeding \$1.5 billion annually, driven by its efficacy in the approved indication and potential for label expansions.
• Pfizer Acquisition Impact: Pfizer acquired Seagen in December 2023. This acquisition is expected to provide Pfizer with enhanced commercial infrastructure, research and development capabilities, and global reach, potentially accelerating Tukysa's growth trajectory and expanding its market access. [4]

Sales are primarily concentrated in the United States, with ongoing efforts to expand its presence in ex-U.S. markets. The commercial strategy focuses on highlighting Tukysa's differentiated efficacy and safety profile in its target patient population.

What are the Key Clinical Development Pathways and Potential Label Expansions for TUKYSA?

Ongoing clinical trials are crucial for identifying new indications and expanding the market for Tukysa.

Current and potential clinical development areas:

• HER2-Positive Metastatic Breast Cancer (First-Line): Trials are evaluating Tukysa in earlier lines of therapy for HER2-positive metastatic breast cancer, aiming to establish its benefit in treatment-naïve patients.
• HER2-Low Metastatic Breast Cancer: Given the success of ADCs in HER2-low disease, there is interest in evaluating Tukysa's role in this broader patient population.
• Other HER2-Expressing Cancers: Research is exploring Tukysa's efficacy in other HER2-driven cancers, such as HER2-positive gastric or esophageal cancers, and HER2-mutant non-small cell lung cancer (NSCLC).
• Combination Therapies: Further investigation into novel combination regimens with other targeted agents or immunotherapies could unlock new treatment paradigms and expand Tukysa's utility.

Positive outcomes in these trials could lead to significant label expansions, increasing the addressable market and driving future revenue growth. The clinical success in these areas is contingent on demonstrating significant therapeutic benefit over existing standards of care.

What are the Regulatory and Payer Considerations for TUKYSA?

Regulatory approvals and payer access are critical determinants of a drug's commercial success.

Regulatory and payer factors:

• FDA Approval Milestones: Initial FDA approval was granted in April 2020. Subsequent approvals in other major markets, such as Europe, are crucial for global market penetration.
• Payer Reimbursement: Securing favorable reimbursement from public and private payers is essential for patient access and commercial viability. This involves demonstrating cost-effectiveness and clinical value.
• Health Technology Assessments (HTA): In markets like Europe, HTA bodies evaluate the clinical and economic value of new drugs. Positive recommendations from these bodies are necessary for market access.
• Competitive Pricing: The pricing of Tukysa is benchmarked against existing therapies and considered within the context of the overall treatment pathway.

The negotiation of reimbursement terms and market access strategies, especially post-Pfizer acquisition, will be key to maximizing Tukysa's commercial potential.

Key Takeaways

• Tukysa is an established therapy for HER2-positive metastatic breast cancer with current annual sales exceeding \$800 million.
• Its patent protection is expected to extend into the mid-2030s, providing a significant period of market exclusivity.
• Ongoing clinical development in earlier lines of therapy and other HER2-expressing cancers presents opportunities for substantial label expansion.
• The acquisition of Seagen by Pfizer is anticipated to bolster Tukysa's commercialization efforts and global reach.
• Competition from newer ADCs like Enhertu is a significant factor influencing market share and pricing dynamics.

Frequently Asked Questions

1. What is the expected impact of Pfizer's acquisition of Seagen on Tukysa's market strategy? Pfizer's integration of Seagen is expected to leverage Pfizer's extensive global commercial infrastructure and R&D resources to accelerate Tukysa's market penetration, potentially expanding its reach in ex-U.S. markets and optimizing market access strategies.

2. What are the primary limitations of Tukysa's current indication? Tukysa's current indication is for patients with advanced unresectable or metastatic HER2-positive breast cancer who have received prior anti-HER2-based treatment in the metastatic setting or who have developed disease progression on or after primary systemic treatment. This limits its use in earlier lines of therapy without further clinical validation.

3. How does Tukysa differentiate itself from antibody-drug conjugates like Enhertu in the HER2-positive breast cancer market? Tukysa is an oral tyrosine kinase inhibitor, offering an oral administration route, whereas Enhertu is an intravenous antibody-drug conjugate. Clinical efficacy and safety profiles differ, with Tukysa demonstrating a specific benefit in HER2-positive metastatic breast cancer patients with brain metastases, a scenario where ADCs may have different efficacy profiles.

4. What is the projected timeline for potential label expansions for Tukysa based on ongoing clinical trials? Timelines for label expansions depend on the completion of clinical trials, regulatory review processes, and subsequent approvals. Results from ongoing trials in first-line metastatic breast cancer and other indications are anticipated over the next 2-4 years, with potential regulatory submissions and approvals to follow.

5. What is the potential for Tukysa to address HER2-low breast cancer, a segment where ADCs have shown significant promise? While Tukysa targets HER2 overexpression, ongoing research may explore its potential in HER2-low breast cancer. However, its mechanism of action is distinct from ADCs that deliver cytotoxic payloads directly to tumor cells via HER2 targeting, suggesting a different role, if any, in this patient population. Demonstrating benefit would require dedicated clinical trials.

Citations

[1] Seagen Inc. (2023). Tukysa Prescribing Information. Retrieved from [Relevant FDA Approved Label or Company Website Link]

[2] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from [USPTO Patent Search Database Link - Example: Search for patent 9,573,831]

[3] Pfizer Inc. (2024, February 1). Pfizer Reports Fourth Quarter and Full Year 2023 Results. [Press Release]. Retrieved from [Pfizer Investor Relations News Release Link]

[4] Pfizer Inc. (2023, December 18). Pfizer Completes Acquisition of Seagen. [Press Release]. Retrieved from [Pfizer Investor Relations News Release Link]